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Abstract.  The transplantation  of cultured myoblasts 
into mature skeletal muscle is the basis for a new 
therapeutic approach to muscle and non-muscle dis- 
eases: myoblast-mediated gene therapy.  The success of 
myoblast transplantation  for correction of intrinsic 
muscle defects depends on the fusion of implanted 
cells with host myofibers. Previous studies in mice 
have been problematic because they have involved 
transplantation  of established myogenic cell lines or 
primary muscle cultures.  Both of these cell popula- 
tions have disadvantages:  myogenic cell lines are 
tumorigenic,  and primary cultures contain a substan- 
tial percentage of non-myogenic cells which will not 
fuse to host fibers. Furthermore,  for both cell popula- 
tions,  immune suppression of the host has been neces- 
sary for long-term retention of transplanted cells. To 
overcome these difficulties, we developed novel culture 
conditions that permit the purification of mouse myo- 
blasts from primary cultures.  Both enriched and clonal 
populations of primary myoblasts were characterized 
in assays of cell proliferation and differentiation.  Pri- 
mary myoblasts were dependent on added bFGF for 
growth and retained the ability to differentiate even af- 
ter 30 population doublings.  The fate of the pure myo- 
blast populations after transplantation  was monitored 
by labeling the cells with the marker enzyme fl-galac- 
tosidase (fl-gal)  using retroviral mediated gene trans- 
fer.  Within five days of transplantation  into muscle 
of mature mice, primary myoblasts had fused with 
host muscle cells to form hybrid myofibers. To exam- 
ine the immunobiology of primary myoblasts, we com- 
pared transplanted  cells in syngeneic and allogeneic 
hosts.  Even without immune suppression,  the hybrid 
fibers persisted with continued fl-gal expression up to 
six months after myoblast transplantation  in syngeneic 
hosts.  In allogeneic hosts, the implanted cells were 
completely eliminated within three weeks. To assess 
tumorigenicity, primary myoblasts and myoblasts from 
the C2 myogenic cell line were transplanted  into im- 
munodeficient mice.  Only C2 myoblasts formed 
tumors.  The ease of isolation, growth, and transfection 
of primary mouse myoblasts under the conditions de- 
scribed here expand the opportunities to study muscle 
cell growth and differentiation using myoblasts from 
normal as well as mutant strains of mice.  The proper- 
ties of these cells after transplantation-the  stability of 
resulting hybrid myofibers without immune suppres- 
sion, the persistence of transgene expression, and the 
lack of tumorigenicity-suggest that studies of cell- 
mediated gene therapy using primary myoblasts can 
now be broadly applied to mouse models of human 
muscle and non-muscle diseases. 
T 
HE mature muscle cells of mammalian  skeletal  mus- 
cle,  known as myofibers,  are multinucleated  syncy- 
tia that arise from the fusion of mononucleated precur- 
sors,  or myoblasts.  Myoblasts persist in mature muscle as 
satellite cells, continue to fuse to adjacent myofibers during 
postnatal growth, and provide a source of cells for new mus- 
cle formation during muscle regeneration  after injury (Cam- 
pion,  1984).  The  first  indication  that myoblasts  could be 
used for therapeutic  purposes was the finding that transplan- 
tation of minced muscle from one animal to another resulted 
in the formation  of hybrid myofibers, which are essentially 
Address all correspondence to Dr. Helen M. Blau, Department of Molecu- 
lar  Pharmacology,  Stanford  University  Medical  Center,  Stanford,  CA 
94305-5332. 
heterokaryons composed of nuclei from both animals  (Par- 
tridge  et al.,  1978).  This  observation led to the idea that 
myoblasts, grown in vitro, could be used as "cell therapy" for 
hereditary muscle diseases (Law, 1982; Watt et al.,  1982; 
Karpati et al.,  1989; Partridge  et al.,  1989; Gussoni et al., 
1992). By fusing with mature or regenerating  fibers of the 
host, implanted myoblasts could form hybrid myofibers thus 
contributing to the syncytium a normal gene product that was 
missing from host muscle. This principle has been most suc- 
cessfully applied to muscular dystrophies in mice (Law et 
al.,  1988b;  Partridge  et al.,  1989).  For example,  the mdx 
mouse, which is the genetic homolog of the human disease 
Duchenne muscular dystrophy, has a defect in the structural 
gene, dystrophin  (Sicinski et al., 1989). In the mouse, as in 
humans,  the absence of dystrophin  leads to focal  muscle 
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tion (Tanabe et al.,  1986). Transplantation  of normal myo- 
blasts into mdx muscle leads not only to the expression of 
dystrophin in hybrid fibers, but also to the protection of those 
fibers from the characteristic pathologic changes (Morgan et 
al.,  1990). 
In addition to the treatment of intrinsic  muscle diseases, 
the  principles  of myoblast transplantation  have  been  ex- 
tended to the treatment of hormone deficiencies (Barr and 
Leiden,  1991;  Dhawan et al.,  1991),  coagulation disorders 
such  as  hemophilia  (Dai  et  al.,  1992;  Yao and  Kurachi, 
1992),  and  even  neurodegenerative  diseases  (Jiao  et  al., 
1993).  For these  conditions,  myoblasts are  engineered  in 
vitro to produce an exogenous gene product.  Upon trans- 
plantation back into muscle or to an ectopic site, the myo- 
blasts act as cellular delivery vehicles by secreting a missing 
or deficient product that is generated as a result of the trans- 
gene expression. 
The mouse is the most commonly used species for studies 
of cell-mediated gene therapy because of the many mouse 
models of human diseases.  However, a major limitation of 
myoblast transplantation in the mouse has been the inability 
to obtain pure populations of primary myoblasts in sufficient 
quantity. Most studies have used primary cultures from dis- 
sociated muscle which are mixtures of myoblasts and non- 
myogenic cells, mostly fibroblasts (Watt et al.,  1982,  1984; 
Law et al.,  1988b;  Partridge  et al.,  1989;  Morgan et al., 
1990; Dai et al., 1992). The non-myogenic cells in these cul- 
tures have a negligible propensity to fuse with muscle cells 
and thus are ineffective in correcting intrinsic muscle defects. 
Furthermore,  under standard culture conditions, fibroblasts 
frequently overgrow the cultures and myoblasts tend to dif- 
ferentiate  and  fuse into  postmitotic,  multinucleated  myo- 
tubes. As a result, the yield of myoblasts from primary cul- 
tures  is  limited  and  transplants  of primary  cultures  are 
heterogeneous mixtures of cells (Morgan, 1988; Jones et al., 
1990).  To date,  no culture conditions have been described 
that permit the preferential growth or extensive proliferation 
of primary mouse myoblasts in vitro. 
As an alternative to heterogeneous mixtures of cells from 
primary cultures,  many investigators  have used pure myo- 
blast populations from established cell lines for transplanta- 
tion (Law et al.,  1988a; Barr and Leiden,  1991; Dhawan et 
al.,  1991;  Yao and Kurachi,  1992).  However, when trans- 
planted into muscle in vivo, these cell lines have a propensity 
to  form  aberrant  muscle  fibers  and  even undifferentiated 
tumors (Wernig et al.,  1991;  Morgan et al.,  1992). More- 
over,  substrate-  and often anchorage-independent  growth, 
unlimited proliferation potential,  and low requirements  for 
serum and growth factors are all typical of cell lines and 
atypical of primary cells.  A  notable exception is the myo- 
genic  MM14  line  which  requires  basic bFGF for growth 
(Clegg et al., 1987). These observations suggest that studies 
of cell growth  and differentiation  properties  in  vitro may 
foretell the behavior of cells in a more complex environment 
such as differentiated tissue in vivo (Rastinejad et al., 1993). 
The transplantation of myoblasts raises questions regard- 
ing muscle immunobiology. There are strains of mice with 
genetic muscle disorders for which no histocompatible myo- 
genic cell lines exist (e.g., the mdx and the dy mice) yet may 
be amenable  to treatment  by cell-mediated  gene therapy. 
Thus the use of cell lines would require immune suppression 
of the host,  which itself may affect the behavior of trans- 
planted myoblasts (Watt,  1982; Hardiman et al.,  1993). In 
theory,  if primary myoblasts were derived from syngeneic 
strains,  then myoblast transplantation  could be performed 
without immune modulation of the host. However, numerous 
observations have indicated immune suppression enhances 
the retention of transplanted  primary cultures (mixtures of 
myogenic and non-myogenic cells) even in syngeneic strains 
(Watt,  1990; Partridge,  1991; Labrecque et al.,  1992). The 
mechanism by which syngeneic cells induce a host immune 
response  remains  obscure,  but  several  investigators  have 
postulated that the inclusion in the transplants of antigen pre- 
senting cells such as fibroblasts may contribute to their rejec- 
tion (Watt,  1990; Watt et al.,  1991).  Taken together,  these 
findings suggest that pure populations of myoblasts from pri- 
mary cultures could overcome the limited host range of cur- 
rently available myogenic cell lines since they can be derived 
from any strain, and could avoid the problems of immunoge- 
nicity of mixed primary cultures. 
Successful treatment of intrinsic muscle diseases by myo- 
blast transplantation requires that host myofibers incorporate 
donor myoblasts.  Hybrid myofiber formation may also be 
critical to efficient systemic delivery of recombinant proteins 
by transplanted,  genetically engineered myoblasts. The as- 
sessment of the efficacy of transplantation  depends on the 
ability to detect such hybrid fibers and distinguish them from 
host fibers that have not incorporated donor cells. For trans- 
plantation  of  normal  myoblasts  into  mdx  mice,  hybrid 
myofibers were identified in situ by the expression of dystro- 
phin, the genetic marker expressed by donor cells but not by 
host fibers (Karpati et al.,  1989; Partridge et al.,  1989). An 
analogous marker of donor cells is necessary to assess the 
consequences  of  myoblast  transplantation  for  hereditary 
muscle diseases of unknown genetic basis and for acquired 
muscle diseases.  Retroviral vectors provide such a method 
of marking  donor cells  (Sanes  et al.,  1986;  Price et al., 
1987). Because these vectors are expressed only in the trans- 
duced cells and their progeny, the expression ofa retrovirally 
encoded protein in a host myofiber would indicate that donor 
cells had been incorporated.  This marking  method allows 
hybrid fibers to be easily distinguished from fibers only of 
host origin (Barr and Leiden,  1991;  Dhawan et al.,  1991). 
However, a concern has been that primary cells may extin- 
guish expression of retroviral vectors after transplantation 
into animals (Palmer et al.,  1991; Scharfmann et al.,  1991). 
To overcome the problems associated with transplantation 
of mixed primary cultures and myogenic cell lines, we have 
established conditions for the purification and propagation 
of pure populations of primary  myoblasts.  The cells were 
first  characterized  in  vitro  with  regard  to  properties  of 
growth and differentiation. Then their differentiation in vivo 
and immunobiology were studied in transplantation assays of 
hybrid fiber formation and tumorigenicity in different strains 
of mice. For monitoring cell fate after transplantation,  cells 
were  labeled  with  the  marker  enzyme  /~-galactosidase 
(fl-gal) ~ by retroviral mediated gene transfer.  After enrich- 
ment, more than 95 % of the cells expressed/~-gal. After in- 
jection into the muscle of syngeneic mice, primary myoblasts 
1. Abbreviations  used in this paper:/3-gal, 15-galactosidase;  H&E, hematox- 
ylin and eosin; X-gal, 5-bromo-4-chloro-3-indolyl-/3-D-galactopyranoside. 
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were stable for up to six months even when there was no im- 
mune suppression of the host, and there was persistent ex- 
pression of the retroviraUy encoded transgene. In aUogeneic 
strains,  the transplanted cells were rapidly rejected.  The 
ability to derive, label,  and transplant primary myoblasts 
from a variety of mouse strains should now permit analysis 
of parameters  of myoblast transplantation critical  to  the 
treatment of intrinsic muscle diseases, the enhancement of 
muscle regeneration, and the systemic delivery of recom- 
binant proteins by genetically engineered myoblasts. Fur- 
thermore, the study of primary myoblasts as muscle stem 
cells can be extended to myoblasts derived from different de- 
velopmental stages, from normal and mutant strains of mice, 
and from strains of mice used as models for human diseases, 
thus expanding the range of myoblast phenotypes that can be 
analyzed in vitro. 
Materials and Methods 
Animals 
Mice were obtained from Simonsen Laboratories, Inc. (Gilroy, CA) (strains 
C57BL/6N,  C3H/HeN,  and BALB/cAnN), from the Jackson Laboratory 
(Bar Harbor, ME) (strains C57BL/10, B6C3Fe), or from the Department 
of Comparative Medicine, Stanford Medical Center (BALB/c/nu/nu). All 
animals were handled in accordance with guidelines of the Administrative 
Panel on Laboratory  Animal Care of Stanford University. 
Preparation of  Primary Cultures 
The forelimbs and hindlimbs were removed from neonatal mice (2-5 d old) 
and  the bones were  dissected  away. The  remaining  muscle  mass  was 
weighed. A few drops of PBS were added and the muscle was minced into 
a coarse slurry using razor blades. Cells were enzymatically dissociated by 
the addition of 2 ml per g of tissue of a solution of dispase (grade II, 2.4 
U/ml, Boehringer  Mannheim  Corp.,  Indianapolis,  IN)  and  collagenase 
(class II, 1%; Boehringer Mannheim Corp.), supplemented with CaC12 to 
a final concentration of 2.5 raM. The slurry, maintained at 37°C for 30-45 
rain, was triturated every 15 rain with a 5-ml plastic pipette, and then  passed 
through 80/~m nylon mesh (Nitex; Tetko, Inc., Monterey Park, CA). The 
filtrate was spun at 350 g to sediment the dissociated cells, the pellet was 
resuspended in growth medium, and the suspension was plated on collagen- 
coated dishes.  During the first several passages of the primary  cultures, 
myoblasts were enriched by preplating (Richler and Yaffe, 1970). 
Culture Conditions 
Growth medium for primary  myoblasts consisted of Ham's F-10 nutrient 
mixture (GIBCO BRL, Gaithersburg, MD) supplemented with 20% FBS 
(HyClone Laboratories,  Inc., Logan, UT) and 2.5 ng/ml bFGF (Promega 
Corp., Madison, WI). Differentiation medium consisted of DME (GIBCO 
BRL) supplemented with 2 % horse serum (HyClone). All media contained 
penicillin G (200 U/ml) and streptomycin (200 ~,g/ml). Tissue culture plas- 
tic dishes were coated with 0.01% type I collagen (Sigma Chemical Co., St. 
Louis, MO).  Cells were grown in a humidified incubator at 37°C in 5% 
CO2. 
In the process of establishing these growth conditions for primary myo- 
blasts, other culture conditions were tested.  In early experiments, DME, 
Waymouth's, or M199 media (GIBCO BRL) were used instead of F-10 in 
the growth  medium.  Other  growth  factors  tested  included  acidic  FGF 
(Promega),  epidermal  growth factor  (Promaga),  platelet derived  growth 
factors AA and BB (UBI, Lake Placid, NY), insulin-like growth factors I 
and II (UBI), and leukemia inhibitory factor (gift of  AMRAD Laboratories, 
Victoria, Australia).  Finally, plastic culture dishes were coated with sub- 
strates  other than  type I  collagen  and  included  laminin  (0.02%,  UBI), 
fibronectin  (0.03%,  Collaborative  Biomedical  Products,  Bedford,  MA), 
and type IV collagen (0.02%, Collaborative Research Products). 
Primary fibroblast cultures were obtained by growing primary cultures 
in DME with  10%  FBS.  Under such conditions,  there was preferential 
growth of fibroblasts which exceeded 99% of the total population after two 
weeks. C2 myoblasts were from the C2C12 subclone derived in this labora- 
tory (Blau et al., 1983) and were grown in a medium of DME supplemented 
with 10% calf serum (HyClone) and 5% FBS. 
Cloning of  Primary Myoblasts 
Primary cultures enriched for myogenic cells (see P,  esults) were plated at 
clonal density and individual clones were isolated using cloning rings when 
the colony size reached ,~50-200  cells. During expansion of the colonies, 
the clones were tested for myogenicity by immunostalning for desmin (see 
below) and by assessing myotube formation in differentiation medium. 
Assessment of Growth and Fusion Indices of 
Primary Myoblasts 
To assess growth properties, 5 ×  104 cells were plated in 35-mm dishes ei- 
ther with different concentrations of bFGF or on different substrates. At 
different times after plating, the number of  cells in each dish was determined 
by hemacytometer counts after the cells were suspended by trypsinization. 
All conditions were tested in triplicate cultures. The concentration of  bFGF 
that produced half-maximal stimulation of growth was calculated as the 
EDs0. The population doubling times of the cells on different substrates 
were determined during periods when cells were in log-phase growth. 
To assess differentiation potential, 5  ×  104 cells were plated in 35-mm 
laminin-coated dishes in growth medium. After 24 h, the growth medium 
was replaced  by differentiation medium.  The  cells  were  maintained  in 
differentiation medium with daily medium changes, and all measurements 
were obtained from triplicate cultures. The fusion index, measm~l daily, 
was determined as the ratio of the number of nuclei in myotubes (cells with 
>13 nuclei) to the total number of nuclei. Ten randomly chosen fields from 
each dish were counted at a magnification of 250x. 
Retroviral Infection of  Myoblasts and Selection of 
Infected Cells 
Retrovirai producer lines were grown in DME supplemented with 10% calf 
serum. The producer cells (~bCRIP  or ~CRE) were grown to confluence and 
the media containing the replication-defective retroviruses BAG (Price et 
al.,  1987) or c~-SGC (Dhawan et al.,  1991) were collected. Both viruses 
contain the lacZ gene encoding the bacterial/~-gal enzyme. The media were 
filtered through 0.45 #m filters, supplemented with 10% FBS and 10 ~tg/mi 
polybrene,  and transferred  to dishes  of primary  myoblasts in log-phase 
growth. The period of exposure to retrovirus ranged from 4 to 12 h, and 
from 2 to 4 infections were performed at 24-h intervals. Each transduced 
culture was tested for helper virus production. Cultures of primary flbro- 
blasts and C2 myoblasts were similarly infected. 
~gal-labeled cells were further enriched by one of two techniques. For 
cultures  infected with the BAG virus,  transduced  cells were  selected in 
growth medium supplemented with 50 ~g/mi G418 (GIBCO BRL) since the 
virus also expresses the neomycin phosphotransferase gene. For cultures in- 
fected with the c~-SGC virus (which does not express a drug resistance 
gene), infected cells were selected by fluorescence-activated cell sorting. 
Cells  expressing/3-gal  produce  a fluorescent product  from the substrate 
fluorescein-di-/5-D-galactopyranoside  and can be purified on that basis (No- 
lan et al., 1988). Infection and selection efficiencies were assessed by stain- 
ing fur B-gal activity (see below). 
Immunofluorescence and Histochemistry on 
Cultured Cells 
Desmin staining.  Cells were fixed in 2 % formaldehyde in PBS for 5 min 
at room temperature followed by 100% methanol at -20"C for 5 rain. The 
cells were then rinsed in PBS. All further incubations were carried out at 
room temperature and all rinses and dilutions were with a blocking solution 
consisting of 2% horse serum and 0.5% Triton-X 100 in PBS. An initial 
blocking step was performed with this solution for 30 rain. An antibody to 
desmin (rabbit polyclonal, Sigma) was applied for 30 min at a dilution of 
1:400. After rinsing, a fiuorescein-coupled secondary antibody (1/250, Cap- 
pel Research Products, Durham,  NC) was applied for 30 rain.  The cells 
were rinsed and stained with the bisbenzirnide dye, HOECHST 33342 (Mo- 
lecular Probes, Inc., Eugene, OR) at 0.2/~M  in PBS for 15 min to stain 
individual  nuclei.  The  percentage  of myogenic  cells  was  determined 
microscopically as the ratio of desmin expressing cells to the total number 
of cells in 10 randomly chosen fields at a magnification of 250×. 
B-gai staining.  Cells  were  fixed with  4%  paraformaldehyde,  0.25% 
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with PBS, the  cells were incubated with  1 mg/mi 5-bromo-4-chloro-3- 
indolyl-B-D-galactopyranoside  (X-gal)  in a solution of 5 mM potassium fer- 
rieyanide, 5 mM potassium ferroeyanide, 2 mM MgC12 in PBS for 8-12 h 
at 37"C (Sanes et al., 1986). Cells expressing/~-gal  produce a blue reaction 
product from the substrate X-gal. The percentage of/~-gal  positive cells was 
determined microscopically as the ratio of the number  of "blue" cells to the 
total number of cells in 10 randomly chosen fields at a magnification of 
250x. 
Cell Transplantations 
Cultured cells were prepared for transplantation by trypsinization, resus- 
pension in growth medium, washing two times with serum-free medium, 
and resuspension in a solution of F-10  with 0.5 % BSA. The final cell density 
for implantation was 2 x  106 -  2 x  107 cells/nil, and the suspension was 
kept on ice. Cell viability in suspension, determined by Trypan blue exclu- 
sion, was greater than 90% after 4 h under these conditions. If the solution 
did not contain BSA, or if the cells were maintained at room temperature, 
cell viability was reduced. Immediately before implantation, the cell sus- 
pension was drawn up into a 25-#1 Hamilton syringe and a 27 gauge needle 
was attached.  Mice, ages 2.5-4 weeks old, were anesthetized with pen- 
tobarbital (60 mg/kg, intraperitoneally) and an incision was made in the 
skin overlying the anterior muscles of the leg, exposing the tibialis anterior 
muscle. All further procedures were done under a dissecting microscope 
which insured that the injections would be targeted to the center of the mus- 
cle and not to the periphery or between muscles. The needle was inserted 
into the belly of the tibialis anterior muscle along the rostro-caudal axis, 
and 5 #1 of the cell suspension was slowly injected while the muscle was 
examined for any leakage. When there were multiple injections into a single 
muscle, the needle was withdrawn slowly and reinserted in the same orien- 
tation, parallel to the first injection. After the final injection, the skin was 
sutured closed. This procedure of injecting myoblasts into an exposed mus- 
cle gave much more reproducible results than did injecting the cells through 
the skin into the muscle. 
Ihmor Assays 
The cells were prepared for injection in the same manner  as for transplanta- 
tion into muscle. For tumor assays, the cells were implanted subcutaneously 
in the flanks of athymic (nu/nu) mice, lightly anesthetized by inhalation of 
methoxyflurane. Into each site,  106 cells were implanted in a volume of 
,o50 #1. The aninlals were examined for the appearance of tumors weekly 
up to 10 weeks. Animals were sacrificed if tumors arose bilaterally. 
Histological Procedures on Frozen Sections 
The animals were sacrificed at different times after the transplantation. The 
tibialis  anterior  muscles  were dissected  free,  embedded  in  mounting 
medium (O.C.T. compound, Miles Laboratory, Elkhart, IN), and frozen in 
isopentane cooled in liquid nitrogen. Cryostat sections were collected on 
gelatin-coated glass slides at regular intervals (every 300-500 #In) along 
the entire length of the tibialis anterior muscle. At each interval, 30-#m and 
10-#m sections were collected. The 10-#m sections were stained with he- 
rnatoxylin and eosin (H&E) and mounted in Pro-Texx mounting medium 
(American Scientific Products, McGraw Park,  IL).  The 30-#m sections 
were fixed and stained for/~-gal activity with X-gal as described above for 
staining of cells in culture. The sections were rinsed in PBS and mounted 
in Alrvol (Air Products and Chemicals, Inc., Allentown, PA). The 30-#m 
sections were analyzed and photographed using Nornarski optics, and the 
number  of/~-gal  positive fibers in a muscle was counted in the cross-section 
with the greatest number  of  labeled fibers. All  analysis and photography was 
performed on a Zeiss Axiophot microscope. 
Results 
Enrichment and Cloning of  Myoblasts from 
Primary Cultures 
We sought to obtain pure populations of myoblasts from pri- 
mary cultures of mouse skeletal muscle which were mixtures 
of myoblasts and fibroblasts. The two cell populations were 
distinguished by staining for the intermediate filament pro- 
tein  desmin,  which  is  expressed  only  in  myogenic  cells 
(Kaufman and Foster,  1988).  Although  the  percentage  of 
myoblasts  could  be  maintained  at  greater  than  70%  by 
preplating  the  cells  at  each  passage  (Richler  and  Yaffe, 
1970),  fibroblasts doubled  more  rapidly and after  several 
days  became  the  predominant cell  type  when  the  growth 
medium consisted of DME  supplemented with 20%  FCS. 
Without preplating, growth of primary cultures resulted in 
fibroblast-enriched populations in which less than 1% of the 
cells expressed desmin. To overcome this problem of fibro- 
blast overgrowth, we tested different culture conditions that 
might preferentially enhance the growth of myoblasts. 
First,  different  nutrient  mixtures  were  tested  for  their 
effects on myoblast and fibroblast growth.  When DME was 
replaced with Waymouth's or M199 media, fibroblasts con- 
tinued to overgrow the cultures. However,  when DME was 
replaced with F-10, myoblasts appeared  to have a  selective 
growth advantage and became the predominant cell type in 
the culture, accounting for more than 95 % of the cell popula- 
tion within two weeks (Fig. 1). This myogenic enrichment in- 
creased further with time in culture. One reason for the im- 
proved growth of myoblasts in F-10 compared with the other 
nutrient mixtures was the low rate of spontaneous myoblast 
Figure L Myogenic enrichment by selective growth conditions. Pri- 
mary cultures from muscle of neonatal C57 mice were grown in 
medium with either F-10 or DME as the nutrient  mixture. After two 
weeks of growth and several passages, one dish of each was fixed 
and stained with an antibody to desrnin to identify myogenic cells 
and with HOECHST nuclear stain to identify all cells. A  single 
field is shown for cells in F-10 (a, c, and e) or DME (b, d, and  f), 
and each is photographed to show morphology (a and b: phase con- 
tras0, total cell number (c and d: HOECHST  nuclear stain) and 
myogenic cells (e andfi desmin staining). Cultures grown in F-10 
were highly enriched for myogenic cells, here  100%,  whereas a 
minority of ceils grown in DME were myogenic. The three myo- 
genic cells in the DME panels are indicated by arrows. Bar, 50 #m. 
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than  3 %  of the myogenic cells in  F-10  expressed myosin 
heavy chain, a  marker of the differentiated state (data not 
shown). In DME, more than 30% of the myogenic cells ex- 
pressed myosin heavy chain and multinucleated myotubes 
were present in the culture. This high rate of differentiation 
in DME removed a large percentage of the cells from the 
proliferating population and allowed fibroblasts to become 
the dominant cell type. When grown in F-10, myoblast en- 
riched cultures had a doubling time of about 30% less (i.e., 
a higher growth rate) than that of fibroblast enriched cul- 
tures. This difference in growth rate accounted for the selec- 
tive growth advantage and progressive enrichment of myo- 
blasts in media with F-10. 
Second, we found that bFGF stimulated the growth of pri- 
mary myoblasts to a greater extent than did other growth fac- 
tors. bFGF produced its maximal mitogenic effect at ,,o2.5 
ng/ml which resulted in a stimulation of the growth rate by 
more than 25 %. The EDs0 of bFGF, a measure of potency 
determined  as  the  concentration producing  half-maximal 
growth stimulation, was *0.5 ng/rnl (Table I). Other growth 
factors, including acidic FGF, platelet-derived growth fac- 
tors AA and BB, insulin-like growth factors I and II, epider- 
mal growth factor, and leukemia inhibitory factor, were less 
efficacious and  less  potent than bFGF  in  stimulating  the 
growth of  primary mouse myoblasts (our unpublished obser- 
vations). 
FinOly, we compared the effect of different substrates on 
the growth rate of primary myoblasts.  Prirnary myoblasts 
grew  poorly  on  tissue  culture  plastic  because  the  cells 
detached easily from the dish. When dishes were coated with 
either type I collagen or laminin,  cells remained adherent 
and the rate of growth of the myoblast population increased 
as evidenced by a reduction in the population doubling time 
(Table I). Type IV collagen and fibronectin were less effec- 
tive as substrates in promoting primary myoblast growth. 
The culture conditions described above, optimized for the 
enrichment and  growth of bulk cultures of primary myo- 
blasts, also allowed the cloning of myoblasts from primary 
cultures.  When myoblast-eafiched cultures were plated at 
low  density  to  achieve clonal  growth,  the  colonies were 
nearly all myogenic as determined by desmin staining. Myo- 
genic clones from several different strains of mice, including 
C57, C3H, Balb/c, and B6C3Fe have been obtained. In each 
case, the properties of clonal myoblast cultures were com- 
Table I.  Comparison of the Phenotypes of Myoblasts 
Enriched or Cloned from Primary Cultures 
Enriched myoblasts  Cloned  myoblasts " 
bFGF response: EDso  0.55 + 0.10 ng/ml  0.48 + 0.17 ng/ml 
Population doubling time 
On collagen (type I)  23 -1- 2 h  22 + 3 h 
On laminin  23 +  1 h  24 + 2 h 
On plastic  44 + 4 h  40 + 4 h 
Fusion index 
Day 3  66%  +  5%  33%  +  3% 
Day 5  72%  -t- 5%  50%  + 9% 
All values are the averages of 3--4 separate experiments and the errors 
represent + SD. 
Figure 2. Retroviral labeling of primary myoblasts. (a) Cloned my- 
oblasts were infected with the BAG virus, selected by addition of 
G418 to the growth medium, and then stained with X-gal to deter- 
mine the percentage of  cell expressing fl-gal (cells with a blue reac- 
tion product). M6re than 95 % of the cells were fl-gal positive. A 
cell not expressing fl-gal is indicated by the arrow. (b) Retrovirally 
labeled myoblasts were induced to differentiate in vitro by growth 
in low serum medium. Even after cloning, expansion in culture, 
retroviral infection, and selection, the cells readily differentiated to 
form linear and branching multinucleated myotubes, fl-gal staining 
shows persistent expression of the transgene in differentiated cells. 
Bars, 80 #m. 
pared to myoblast-enriched cultures.  The cell populations 
were indistinguishable morphologically. Added bFGF stim- 
ulated equally the growth of enriched and clonal cultures of 
primary myoblasts with an EDs0 of •0.5  ng/ml (Table I). 
When grown on type I collagen or laminin, both cell popula- 
tions had a doubling time of ,,024 h; both grew more slowly 
on tissue culture plastic. When switched to medium with low 
serum to induce differentiation, both clonal and enriched 
myoblasts  formed twitching  myotubes (see Fig.  2  b),  al- 
though the clones generally formed myotubes more slowly 
than enriched cultures. In sum, except for a difference in the 
rate of differentiation, the properties of clonal and enriched 
cultures of mouse myoblasts were similar. 
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myoblast transplantation  into 
syngeneic and allogeneic hosts. 
~-gal-labeled  primary  myo- 
blasts  were transplanted  into 
the muscles of C57 mice and 
the muscles were examined at 
different times thereafter. Mus- 
cles were frozen and cryostat 
sections were collected for his- 
tological analysis. Photomicro- 
graphs are from muscles taken 
5 d (left) and 3 wk (righO after 
transplantation. For each trans- 
plant,  a pair of adjacent sec- 
tions is shown: the first (top) is 
stained  for f3-gal activity  to 
follow the  fate  of implanted 
cells;  the  second  (bottom) is 
stained with H&E for routine 
histology. The results of  trans- 
plantation of syngeneic (C57) 
and  allogeneic  (C3H) myo- 
blasts  are  shown  in  the 
top  four  panels  and  bottom 
four panels, respectively. Bar, 
60 #m. 
Both clonai and enriched cultures of primary myoblasts 
displayed remarkable proliferation potential. Pure myoblast 
cultures from several mouse strains have been expanded be- 
yond 40 population doublings, and some clonai cultures have 
been expanded beyond 50 population doublings (>10 ~ cells 
per clone). There were no detectable changes of growth rate 
or  cell  morphology  even  after  extensive  proliferation  in 
vitro. Because of the extraordinary growth potential of pri- 
mary myoblasts under these culture  conditions,  the trans- 
plantation studies described below were made possible and 
were not limited by the number of available cells. 
Retroviral Infection of Primary Myoblasts 
Primary myoblasts were infected with replication-defective 
retroviruses encoding ~-gal (see Methods) in order to follow 
their fate of transplantation.  The efficiency of retroviral in- 
fection was assessed by staining the cells for ~-gal activity 
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tion product formed. In most cases, between 30 and 50% of 
primary myoblasts expressed/3-gal after retroviral infection. 
Both drug selection and fluorescence-activated cell sorting 
(see Methods) were used to purify retroviral-labeled myo- 
blasts from the population. With either method, over 95 % 
of the selected population expressed/$-gal (Fig. 2 a).  This 
high enrichment was maintained during extended growth in 
vitro. In addition, when the cells were induced to differenti- 
ate in low serum medium, ~-gal continued to be expressed 
in the resulting multinucleated myotubes (Fig. 2 b). 
Hybrid Myofibers Formed  by Primary 
Myoblast Transplantation 
The success of myoblast transplantation for correction of in- 
trinsic muscle defects depends on the ability of implanted 
myoblasts to fuse directly to host muscle cells, thus forming 
hybrid myofibers. To determine whether primary myoblasts 
would  form  such  hybrids,  retrovirally labeled  myoblasts 
were implanted into the tibialis anterior muscles of syn- 
geneic host mice and the muscles were examined five days 
later (Fig. 3). Hybrid fibers were identified as fibers of nor- 
mal diameter (>30 t~m) that were/~-gal positive, and were 
evident surrounding the implantation site as well as along the 
needle track. These large fibers, which had diameters com- 
parable to neighboring unlabeled host fibers, most likely 
arose from the fusion of implanted cells with host fibers. By 
contrast, at the center of the implantation site where there 
was injury to host muscle, there were discrete foci of/3-gal 
labeled myotubes and small regenerating fibers (<15 #m in 
diameter) among /~-gal labeled mononucleated cells.  The 
myotubes and small fibers may have arisen from the fusion 
of implanted cells with each other or with host muscle that 
was regenerating. Because it is not possible to distinguish 
hybrid regenerating fibers from fibers only of donor myo- 
blast origin, these small fibers were not included in the anal- 
yses of hybrid myofiber formation. 
When muscles were examined three weeks after transplan- 
tation,  hybrid myofibers were  evident amidst the normal 
muscle architecture (Fig.  3).  At this time, mononucleated 
cells expressing/~-gal were rarely seen. There still remained 
small diameter,/~-gal positive fibers (see Fig. 7 for an exam- 
ple) at the center of the implantation site, and these fibers 
never achieved normal caliber but remained as a central clus- 
ter of aberrant (small) fibers even months later. The numbers 
of hybrid myofibers determined five, ten, and twenty-one 
days after transplantation were essentially constant (Fig. 4). 
Thus the hybrid fibers counted five days after transplantation 
probably represent a population that is constant and distinct. 
The formation of  hybrid fibers appears to be the predominant 
fate of implanted primary myoblasts. 
As a control that the labeling of  host fibers with/%gal arose 
from the fusion of implanted myoblasts and not from the di- 
rect transfer of genetic material (Kaleko et al.,  1990),  we 
performed syngeneic transplants of fibroblast enriched cul- 
tures that were/~-gal labeled by retroviral transduction. Mus- 
cles were examined two days to six weeks after transplanta- 
tion of 1@  -  4  x  105 fibroblasts. Within several days of 
transplantation,  the  muscle had  a  mass  of/3-gal  labeled 
mononucleated cells at the site of implantation (data not 
shown). In most of the muscles examined, no/~-gal labeled 
myofibers were detected, and the maximum number of/3-gal 
labeled fibers in any given muscle was four. Previous work 
has shown that fibroblasts may fuse spontaneously with myo- 
genic cells at a low frequency (Chaudhari et al., 1989) which 
would account for the occasional #-gal labeled fibers seen 
here. Alternatively, the few/3-gal labeled fibers arose from 
the fusion of  rare myogenic cells present in the cultures (<1% 
of cells in the fibroblast enriched cultures expressed des- 
min). In either case, the paucity of labeled fibers after fibro- 
blast  transplantation indicate that the  results  with  trans- 
planted myoblasts, namely a large number of labeled fibers, 
are unlikely to be due to a rearrangement and uptake of the 
lacZ gene within the tissue. Rather, the detection of/3-gal 
within  myofibers  after  myoblast  transplantation  clearly 
reflects the propensity of the implanted cells to undergo cell 
fusion. 
Long-Term Stability of  Hybrid Myofibers 
without Immune Suppression 
Previous studies of transplantation of mixed primary cul- 
tures from muscle indicated that long-term survival of trans- 
planted  ceils  required  immunosuppression,  even  in  syn- 
geneic hosts (Watt,  1990;  Labrecque et al.,  1992).  It was 
suggested that the immune response generated against donor 
tissue was due to the presence of  donor immune cells or anti- 
gen presenting  cells,  such  as  fibroblasts  and  endothelial 
cells, in the transplanted cell population (Watt,  1990;  Watt 
et al., 1991). We therefore performed experiments to deter- 
mine whether the use of pure populations of primary myo- 
blasts could overcome this problem. Moreover, the lack of 
evidence of immune rejection three weeks after transplanta- 
tion in our experiments suggested that it might be possible 
to achieve long-term stability of hybrid myofibers without 
immunosuppression. To test this possibility, we determined 
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Figure 4. Hybrid fibers formed by syngeneic and allogeneic myo- 
blast transplantation. From experiments such as those shown in 
Fig. 3, the numbers of hybrid fibers (normal diameter and/~-gal 
positive) were counted for each transplant. For syngeneic  myoblast 
transplantation, hybrid myofibers  were formed within 5 d of trans- 
plantation and the number of these fibers changed little during the 
next two weeks. For allogeneic myoblast transplantation, despite 
early hybrid myofiber formation, there was complete rejection of 
transplanted cells by three weeks. Error bars, :t: SD; n = 6 for each 
point. 
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after transplantation  of fl-gal  labeled  primary  myoblasts. 
There was no diminution of the intensity of/~-gal staining be- 
tween one and six months after transplantation (Fig. 5 a) in- 
dicating that expression of the retroviral vector was not shut 
off, and that retrovirally encoded/3-gal could be used as a 
permanent marker of hybrid fibers  for long-term experi- 
ments. The number of hybrid fibers remained within a re- 
markably constant range up to six months after transplanta- 
tion (Fig. 5 b). These results suggest that hybrid myofibers 
formed by incorporation of syngeneic primary  myoblasts 
may be stable indefinitely without immune suppression. 
We hypothesized that hybrid fibers formed by the trans- 
plantation of allogeneic myoblasts might also be stable with- 
out immunosuppression. There is substantial evidence that 
mature myofibers express neither class I nor class II major 
histocompatibility molecules (Ponder et al.,  1983; Karpati 
et al.,  1988). From the data with syngeneic transplants, we 
knew  that  implanted myoblasts became incorporated into 
host fibers within five days of transplantation. We therefore 
postulated that allogeneic cells would also rapidly become 
incorporated into mature fibers and would thus be protected 
from immune rejection because of the lack of expression of 
major histocompatibility molecules on the hybrid fibers. To 
test this possibility, we transplanted ~-gal labeled myoblasts 
into the muscles of allogeneic host mice. The muscles were 
examined for hybrid fiber formation five, ten, and twenty- 
one days after transplantation.  Five days after transplanta- 
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Figure 5. Long-term stability of hybrid myofibers from syngeneic 
myoblast transplants  without  host  immune  suppression,  fl-gai- 
labeled primary myoblasts were transplanted into syngeneic hosts 
and the muscles were analyzed at different times up to 6 months 
after transplantation. (a) There is no change in the appearance of 
the hybrid fibers or the intensity of/~-gal staining between one and 
six months after transplantation. Bar, 30/~m.  (b) The number of 
hybrid fibers remained within a narrow range without any diminu- 
tion up to six months after transplantation. Each point represents 
an individual muscle. 
Figure  7.  Comparison  of primary  and C2 myoblast transplants. 
Cloned primary myoblasts and C2 myoblasts, both labeled with the 
fl-gal marker, were transplanted into muscles of athymic mice, and 
the muscles were analyzed for fl-gal positive fibers at different times 
thereafter. Both panels are from muscles examined six weeks after 
transplantation. (a) Primary myoblast transplant: nearly all of the 
fl-gal positive cells are normal caliber fibers. A single small di- 
ameter fiber in this field is indicated by the arrow. (b) C2 myoblast 
transplant: A majority of fl-gal-labeled cells were fibers of small 
diameter and intensely stained for fl-gai activity (arrows). These 
small fibers most likely arose from C2 myoblasts fusing with each 
other. Bar, 15/~m. 
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number of such fibers was only ,x,20% less than after syn- 
geneic transplants (Fig. 4). Five days later (day 10), however, 
there was massive infiltration of the transplant by inflamma- 
tory cells with local tissue destruction and a reduction in the 
number of hybrid fibers (Fig. 4). By three weeks after trans- 
plantation, all evidence of implanted myoblasts had vanished 
and the immune response had completely resolved (Figs.  3 
and 4).  Clearly, for allogeneic transplants, even myoblasts 
that had fused to mature fibers were not protected from im- 
mune rejection. 
blasts was to form hybrids with host myofibers. The fusion 
of implanted ceils exclusively with each other was uncom- 
mon except at the very center of the implantation site, and 
the persistence of implanted cells as mononucleated cells 
was rare. In contrast, transplantation of myoblasts from es- 
tablished cell lines has resulted both in new muscle forma- 
tion and undifferentiated tumors (Wernig et al., 1991; Mor- 
gan et al., 1992), although no marker of implanted ceils was 
used in these studies. To compare directly the fates of pri- 
mary myoblasts and myoblasts from the C2 myogenic cell 
line, each population was labeled with #-gal and transplanted 
Enhancement of  Hybrid Myofiber Formation 
Because the beneficial effects of myoblast transplantation for  a 
intrinsic muscle diseases depends on the fusion of the im- 
planted cells with the diseased fibers, it is desirable that im-  m  300 
planted myoblasts fuse with as many hosts as possible. We 
explored two ways to increase the number of hybrid fibers  u, 
formed. The first method was to determine whether incorpo- 
ration into fibers could be increased by increasing the num-  w 
bet of myoblasts implanted. When individual muscles were  o  200 
given one, two, or three injections, the number of hybrid  "~ 
myofibers formed correlated with the number of injections 
and thus the number of implanted myoblasts (Fig. 6 a). The 
number of 5 #1 injections was essentially limited to three be- 
cause the tibialis anterior muscle, swollen with the 15 pl of 
100 
cell suspension, could not retain much more volume. As an 
alternative, the density of the ceils in suspension for a single 
injection was varied. Again, the number of hybrid fibers in- 
creased with the number of ceils injected for cell densities 
0 
between 5  x  104 and 2  x  105 myoblasts per 5/zl (Fig. 6 b).  o 
Higher cell densities did not yield proportionate increases of 
hybrid fibers.  These data show that the number of hybrid 
fibers formed can be increased by increasing the number of 
myoblasts implanted within a given range. 
As a  second method to increase the number of hybrid  b 
myofibers formed, we attempted to induce implanted myo- 
blasts to migrate to distant regions of the muscle. Recent  _~  200 
data have suggested that implanted myoblasts have the capac-  u. 
ity to migrate from the site of  implantation to areas of  muscle  .~ 
injury, even into adjacent muscles (Morgan et al., 1993). To  -~ 
test for such migration and perhaps to induce the formation  a.  ° 
of hybrid myofibers throughout the muscle, we injured the  "a 
tibialis anterior muscle either lateral to the myoblast implan- 
~"  I00  tation site or caudal to it, i.e.,  along the axis of the host  "6 
fbers. Injuries were made either by forceps crush or by local 
application of solid COs.  In different groups of mice, mus- 
cles were injured 3 d before, simultaneously with, or 3 d af- 
ter myoblast implantation. The muscles were examined 2 wk  ~" 
later when most muscle regeneration was complete. In no 
case were/~-gal labeled fibers or mononucleated cells seen  0 
in the regenerated muscle, and the numbers of/3-gal labeled  0 
fibers at the implantation site were never greater than in 
uninjured muscle. Under these experimental conditions, we 
were unable to detect any injury-induced migration of im- 
planted  myoblasts or  consequent enhancement of hybrid 
myofiber formation. 
In Vivo  Proliferation and Tumor Formation by C2 
Myoblasts But Not by Primary Myoblasts 
Our data indicated that the predominant fate of  primary myo- 
I  I  I 
1  2  3 
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Number of Myoblasts  (x 10 $ )  per Injection 
Figure 6.  Relationship between the number of myoblasts trans- 
planted and the number of hybrid fibers formed. Syngeneic 3-gal- 
labeled myoblasts  were transplanted into either C57 or C3H hosts, 
and the number of/3-gal positive fibers were counted 2-3 wk after 
transplantation. The number of hybrid myofibers  formed could be 
increased either by (a) increasing the number of injections (with a 
constant number of cells per injection); or (b) increasing the num- 
ber of cells implanted via a single injection. Error bars represent 
+  SD; n =  4-6 for each point. 
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from two weeks to three months later. 
As in syngeneic hosts, primary myoblasts formed hybrid 
myofibers with host muscle (Fig. 7 a), and the number of hy- 
brid fibers remained stable for months. Persisting B-gal posi- 
tive myoblasts were rare, and small diameter fibers express- 
ing/3-gal (Fig. 7 a) constituted a small percentage of  all/3-gal 
labeled fibers. Therefore, just as in syngeneic hosts, fusion 
to host fibers again appeared to be the predominant fate of 
transplanted primary myoblasts. 
The fate of implanted C2  myoblasts was more variable 
than that observed for primary myoblasts. Even though fu- 
sion of  C2 myoblasts to host fibers was evident from the pres- 
ence of ~-gal labeled fibers of normal caliber, a majority of 
the B-gal labeled fibers were of small diameter (Fig. 7 b). 
These small fibers were more intensely stained for/~-gal, 
their numbers increased with time, and they were densely 
packed at the center of the implantation site, features that all 
suggested that they arose from the fusion of C2 myoblasts 
with each other. As a result, the muscle architecture became 
increasingly distorted (Fig. 7 b).  Such new muscle forma- 
tion, arising from the fusion of implanted cells with each 
other, would be a fruitless outcome in an attempt to form hy- 
brid myofibers for the correction of intrinsic muscle deficits. 
A propensity to form tumors is undesirable for any cells 
transplanted for cell-mediated gene therapy. There was no 
evidence of uncontrolled proliferation of primary myoblasts 
after transplantation into muscle. To test tumorigenic poten- 
tial more stringently, we implanted primary and C2 myo- 
blasts into subcutaneous sites in athymic mice and assessed 
the mice for tumor formation for 10 wk. Implantation of C2 
myoblasts produced tumors in three of four sites (Table II). 
These tumors were first visible at 5, 7, and 8 wk. In contrast, 
primary myoblasts produced no detectable tumors at any of 
twelve implantation sites.  This low tumorigenic potential is 
further evidence that primary myoblasts are preferential to 
myoblasts from established cell lines  for studies of cell- 
mediated gene therapy. 
Discussion 
The formation of hybrid myofibers by the fusion of implanted 
myoblasts with host muscle is the basis of myoblast trans- 
plantation for the  correction of intrinsic muscle diseases 
(Partridge,  1991). The fusion of donor myoblasts to host 
myofibers allows donor cells to contribute their normal gene 
products to the syncytial myofiber, thus replacing any miss- 
ing or defective gene product in the host. For efficient sys- 
temic delivery of recombinant proteins by genetically en- 
gineered myoblasts,  it may also  be  necessary  for donor 
myoblasts to fuse to host fibers. The results presented here 
demonstrate that pure populations of primary myoblasts are 
an excellent source of such donor cells: (a) primary myo- 
Table II. Tumorigenicity  of  Different Myoblast Populations 
Tumor formation 
Cell type  (# sites with tumors/total # sites) 
Enriched primary rnyoblasts  0/6 
Cloned primary myoblasts  0/6 
C2 myoblasts  3/4 
blasts have a remarkable proliferative capacity in vitro; (b) 
their predominant fate after transplantation is fusion to host 
fibers; (c) the hybrid fibers formed are stable in syngeneic 
hosts without immune suppression; and (d) primary myo- 
blasts appear to have no propensity to continue proliferating 
in an uncontrolled manner in vivo or to form tumors. The 
conditions described here allow purification and expansion 
of primary myoblast populations in a manner previously not 
possible. As a result, these cells can now be used to over- 
come the limitations of mixed primary cultures and myo- 
blasts from established cell lines used in previous studies of 
myoblast transplantation  (Watt  et  al.,  1982;  Law et  al., 
1988a, b; Partridge et al., 1989; Morgan et al., 1990). Thus 
myoblasts can be taken full cycle from the animal to the cul- 
ture dish and back to the animal. 
The benefits of being able to obtain pure populations of 
primary mouse myoblasts extend beyond studies of myoblast 
transplantation. Primary myoblasts can be viewed as stem 
cells or self-renewing tissue precursors. As such, they offer 
the opportunity to study the stages of muscle differentiation 
in vitro. The ability to purify myoblasts from various strains 
of mice, from different developmental stages, and from mice 
with various hereditary muscle diseases expands the pheno- 
typic range of muscle cells amenable to analysis in vitro. 
These include myoblasts from mutant mouse strains that 
serve as models for human myopathies (Partridge, 1991). To 
such, mutant strains can be added transgenic and "knock- 
out" strains of mice that further expand the genotypic range 
of myoblasts  whose  study  may  shed  light on  important 
aspects of cell growth, migration, and differentiation (Braun 
et al., 1992; Rudnicki et al., 1992). Finally, the proliferative 
capacity of primary myoblasts allows genetic engineering of 
these cells in vitro potentially providing an unlimited num- 
ber of variants, including myogenic mutants derived from 
gene targeting in culture. 
Although culture conditions have been established for the 
clonal growth of chick, rat, and human myoblasts (Konigs- 
berg,  1961; Richler and  Yaffe, 1970;  Blau and Webster, 
1981), no previous reports have described conditions for the 
successful cloning of mouse myoblasts. Investigators have 
therefore turned to techniques for enriching myoblasts from 
mouse primary cultures (Richler and Yaffe, 1970;  Morgan, 
1988; Jones et al., 1990). The major drawback of all of these 
techniques has been that the enrichment has been transient 
since fibroblasts eventually overtake the cultures. Further- 
more, all of the techniques lead to a substantial reduction in 
the total yield of myogenic cells. By contrast, the culture 
techniques described here allow the preferential growth of 
myoblasts over fibroblasts, and the yield of myogenic cells 
from the initial primary culture is very high. Moreover, the 
percentage of myogenic cells increases with time in culture. 
Thus, from a mixed culture of myoblasts and fibroblasts, a 
nearly pure culture of myoblasts (>99%) is achieved within 
three weeks. Though not rapid, the enrichment is permanent 
and proceeds as the cultures are expanded. Equally impor- 
tantly, the same culture conditions allow the growth of pri- 
mary mouse myoblasts at clonal density. Thus, the culture 
conditions described here are suitable for studies of either 
bulk or clonal populations of mouse myoblasts. 
Cloned and enriched myoblast populations had similar 
growth properties in vitro including bFGF dependence, sub- 
strate dependence, and growth potential. As an extension of 
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fiber formation and tumorigenicity also revealed little differ- 
ence between these populations. By contrast, C2 myoblasts 
had much less stringent requirements for growth in vitro and 
were more disruptive of normal muscle architecture after 
transplantation. If the implantation of cultured myoblasts is 
to be used as a model system for the study of normal muscle 
differentiation  and repair (Morgan et al., 1992), then in vitro 
characterization may indicate which myoblast populations 
are best suited for that purpose.  Despite their remarkable 
growth potential, primary myoblasts do not have the propen- 
sity  to  form  aberrant  muscle  fibers  or  undifferentiated 
tumors typical of cells from established myogenic cell lines 
(Wernig et al.,  1991; Morgan et al.,  1992). 
Introduction of exogenous genes into cells using retroviral 
vectors has allowed the constitutive expression of the genes 
in transduced cells and their progeny (Sanes et al.,  1986; 
Price  et  al.,  1987).  The  observation  of  inactivation  of 
retroviral genes in primary cells after transplantation has 
been viewed as a potential obstacle for the use of primary 
cells for cell-mediated gene therapy (Palmer et al.,  1991), 
but other reports have been more encouraging (Scharfmann 
et al., 1991). Dai et al. (1992) used retroviral mediated gene 
transfer to engineer mixed primary muscle cultures to pro- 
duce factor IX. After transplantation of the ceils in vivo, the 
transgene was expressed for up to six months. However, the 
percentage of myogenic cells in the injected population was 
unknown and there was no evidence that the implanted myo- 
blasts had fused to host fibers since the fate of the implanted 
cells was not examined. We found that retroviral transduc- 
tion of  primary myoblasts with the lacZ gene led to persistent 
expression of ~-gal in vitro and in vivo. The intensity of  ~-gal 
staining in mature myofibers was as robust six months after 
transplantation as after two weeks. Thus, constitutive trans- 
gene expression after retroviral transduction appears to be 
as feasible with primary myoblasts as with established cell 
lines, which is promising for the use of primary myoblasts 
for cell-mediated gene therapy. 
Retroviral labeling of primary myoblasts with/~-gal per- 
mitted the elucidation of their fate after transplantation. The 
possible fates of transplanted myoblasts include fusion to 
mature fibers of the host, fusion to regenerating muscle cells 
of the host, fusion to other implanted myoblasts, persistence 
as mononucleated cells (either quiescent, proliferating, or 
differentiated), or death. We do not know the extent of cell 
death among the implanted population, but the predominant 
fate of surviving cells is fusion to mature, host fibers. The 
persistence of primary myoblasts as mononucleated cells ly- 
ing outside muscle fibers was rarely observed. Ceils from 
mixed primary cultures are unlikely to have such a uniform 
fate after transplantation. Non-myogenic cells such as fibro- 
blasts present in the population persist in the muscle inter- 
stitium and could produce adverse effects on muscle tissue 
such as increased interstitial connective tissue. Thus, the use 
of pure populations of myogenic cells is clearly preferable. 
Of particular importance is the demonstration of long- 
term survival of the implanted primary myoblasts without 
immunosuppression. Several previous reports have indicated 
poor  survival of myoblasts or minced muscle transplants 
even when donor and host were matched at major histocom- 
patibility loci (watt,  1990;  Partridge,  1991; Labrecque et 
al.,  1992).  This poor survival has been interpreted as im- 
mune rejection related to antigen presenting cells such as 
fibroblasts or endothelial cells in mixed cultures, or to the 
inclusion of donor inflammatory cells  in minced muscle 
(Watt,  1990; Watt et al., 1991). Thus myoblast transplanta- 
tion studies are routinely performed with immunosuppres- 
sion even in syngeneic hosts, in immunodeficient  mice, or in 
mice made tolerant neonatally to donor cells (Morgan et al., 
1990; Chen et al., 1992; Dai et al., 1992).  The use of pure 
populations of myoblasts avoids the potential problem of 
contaminating cells. In our studies, even after weeks in cul- 
ture and introduction and expression of a foreign gene, the 
primary myoblasts were incorporated into mature muscle 
and stably expressed a transgene for up to six months after 
transplantation without any immune modulation of the host. 
The use of immunocompetent hosts is not only simpler, but 
also preferable since altering the immunologic state of the 
host could potentially affect the fusion of transplanted myo- 
blasts (Watt,  1982;  Hardiman et al.,  1993).  Furthermore, 
immunosuppressive agents may be  directly toxic to host 
muscle (Le Quintrec and Le Quintrec, 1991) and may them- 
selves have effects on muscle disease processes. It is thus best 
to avoid the complications of immunosuppressive therapy in 
studies of muscle diseases using myoblast transplantation. 
Although  myoblasts  transplanted  into  syngeneic  hosts 
were retained without immune suppression, myoblasts trans- 
planted into allogeneic hosts were subject to immune rejec- 
tion. Watt et al.  (1991) assessed the long-term survival of 
mixed cells from primary cultures injected into non-histo- 
compatible hosts. The cells were injected into a minced au- 
tograft of  host muscle and were rapidly rejected in more than 
90 % of the experiments. However, in a few cases, there was 
evidence of survival of donor myogenic ceils seven weeks af- 
ter transplantation. It may be possible for some allogeneic 
myoblasts to become incorporated into host fibers and per- 
sist in an immunologically protected environment since ma- 
ture fibers express neither class I nor class II major histo- 
compatibility molecules (Ponder et al., 1983; Karpati et al., 
1988).  In  our  experiments,  transplantation of allogeneic 
myoblasts resulted  in  complete  elimination of implanted 
cells within three weeks despite the fact that extensive fusion 
to  mature fibers was  seen  five days after transplantation 
(Figs. 3 and 4). It may be that the specific strain combina- 
tions of host and donor may account for the differences in 
results (Butcher and Howard, 1982). We are currently inves- 
tigating whether transient immune suppression,  until the 
time when all persisting cells have become incorporated into 
mature fibers,  could prevent rejection and allow primary 
myoblasts to persist indefinitely in allogeneic hosts without 
sustained immune suppression. 
Several investigators have reported that endogenous mus- 
cle precursor cells are able to migrate toward areas of  muscle 
damage to participate in the regenerative process (Schultz et 
al., 1985; Phillips et al., 1990). We found no evidence of the 
movement of implanted myoblasts to nearby areas of muscle 
regeneration. Recently, Morgan et al.  (1993) reported evi- 
dence of migration of implanted myoblasts into adjacent 
muscles. The results are not directly comparable to ours be- 
cause of  the added variables in their studies: the host animals 
were immunodeficient, their limbs were exposed to high lev- 
els of X-irradiation before implantation to kill endogenous 
muscle  precursor  cells,  and  the  muscle  was  dystrophic. 
When no irradiation was given, no migration was observed. 
Rando and Blau Primary Mouse Myoblast Transplantation  1285 Previous work by these authors also suggested that migration 
of endogenous muscle precursor cells occurred only with 
widespread degeneration of host muscle and that evidence of 
such  migration  was  more  likely  to  be  observed  in  im- 
munodeficient  hosts (Watt et al.,  1987). Together with our 
results,  these observations suggest that the mobility of im- 
planted myoblasts may indeed be quite limited except under 
specific experimental  conditions. 
These studies of the characterization  in vitro and in vivo 
of primary myoblasts are encouraging  for their use in trans- 
plantation  studies  in mice.  Investigations  into muscle im- 
munobiology beyond those presented here should  unravel 
some of the conflicts  of retention  and  rejection of trans- 
planted  myoblasts  under different  conditions.  The ease of 
isolation, expansion,  and retroviral infection of pure popula- 
tions  of mouse myoblasts  should  lead to further improve- 
ments in the efficiency as well as a better understanding  of 
the immunology and tissue biology of myoblast transplanta- 
tion.  Such advances are critical to the improvement  of cur- 
rent methods used for human trials  of myoblast-mediated 
gene therapy,  such  as those for Duchenne muscular dys- 
trophy (Gussoni et al., 1992; Karpati et al., 1993; Tremblay 
et al.,  1993). 
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